PQQ (pyrroloquinoline quinone) is studied for stimulating mitochondrial biogenesis. This article reviews the evidence for energy, cognition, and how PQQ pairs with CoQ10 and NMN.
PQQ and Mitochondrial Biogenesis is one of the more compelling topics in cellular nutrition research right now. Pyrroloquinoline quinone (PQQ) has drawn attention for its potential role in stimulating the growth of new mitochondria — a process called mitochondrial biogenesis — which matters because mitochondrial function declines with age and is linked to fatigue, metabolic slowdown, and cognitive impairment. But the gap between cellular studies and meaningful human outcomes is wide, and it's worth examining what the evidence actually shows before drawing any conclusions about supplementation.
What the Research Actually Shows
Most of the evidence for PQQ's effects on mitochondria comes from in vitro and animal studies. In cultured cells and rodent models, PQQ has been shown to activate signaling pathways associated with mitochondrial biogenesis, particularly through PGC-1α — the master regulator of mitochondrial growth and function. These findings are mechanistically interesting, but they do not automatically translate to humans.
Human data on PQQ and mitochondrial biogenesis specifically is limited. A few small randomized trials have examined PQQ supplementation for outcomes like cognitive function, fatigue, and sleep quality — but these studies typically use composite supplements or combine PQQ with CoQ10, making it difficult to isolate PQQ's independent effects. The sample sizes are generally small (often under 50 participants), study durations are short (8–12 weeks), and the primary endpoints are subjective measures rather than direct assessments of mitochondrial density or function.
There is no published human trial that directly measures mitochondrial biogenesis — via muscle biopsy for mitochondrial DNA copy number, citrate synthase activity, or respirometry — in response to PQQ supplementation alone. This is a critical gap. Until such data exists, claims that PQQ "grows new mitochondria" in humans remain speculative.
| Study Type | Population | PQQ Dose | Duration | Key Finding | Evidence Quality |
|---|---|---|---|---|---|
| Animal / In Vitro | Rodents, cell cultures | Varied (mg/kg) | Days to weeks | PGC-1α activation, increased mitochondrial markers | High (mechanistic) |
| RCT (composite supplement) | Healthy adults | 20 mg PQQ + CoQ10 | 8 weeks | Improved subjective fatigue scores | Moderate |
| RCT (PQQ alone) | Middle-aged adults | 20 mg/day | 12 weeks | Improved sleep quality, reduced stress (cortisol) | Low–Moderate |
| Human (direct biogenesis) | None published | N/A | N/A | No direct human data on mitochondrial biogenesis | Not available |
The Mechanism: How PQQ Might Work
PQQ is a redox cofactor — meaning it participates in electron transfer reactions — and it is structurally distinct from more familiar cofactors like NAD+ or FAD. Its primary proposed mechanism for mitochondrial biogenesis centers on the activation of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), which coordinates the transcription of nuclear genes required for mitochondrial replication and function.
PGC-1α is activated by multiple upstream signals, including AMPK (AMP-activated protein kinase) and SIRT1 (a NAD+-dependent deacetylase). PQQ appears to influence this pathway, though the exact molecular target remains unclear. Some evidence suggests PQQ may act as a signaling molecule rather than a direct enzyme cofactor in this context — triggering kinase cascades that ultimately upregulate PGC-1α and downstream mitochondrial genes like TFAM (mitochondrial transcription factor A), NRF-1, and NRF-2.
PQQ also exhibits antioxidant properties, scavenging reactive oxygen species (ROS) and potentially protecting existing mitochondria from oxidative damage. This is a separate but related benefit: preserving mitochondrial integrity is not the same as creating new mitochondria, but both contribute to overall mitochondrial health. The distinction matters for consumers evaluating marketing claims.
How PQQ Compares to Other Mitochondrial Supporters
PQQ is often discussed alongside compounds with stronger human evidence for mitochondrial support. Understanding these differences helps set realistic expectations.
Nicotinamide mononucleotide (NMN) is a direct precursor to NAD+, a coenzyme essential for mitochondrial energy metabolism and sirtuin activity. Unlike PQQ, NMN has been studied in human randomized controlled trials with direct metabolic endpoints. Yoshino et al. (2021) demonstrated that NMN supplementation increased muscle insulin sensitivity in prediabetic women. Igarashi et al. (2022) found that chronic NMN supplementation elevated blood NAD+ levels and altered muscle function markers in healthy older men. Irie et al. (2020) confirmed that oral NMN administration raises nicotinamide metabolite levels in healthy Japanese men. Liao et al. (2021) showed enhanced aerobic capacity in amateur runners. These studies do not measure mitochondrial biogenesis directly either, but they assess functional outcomes tied to mitochondrial and metabolic health with more rigor than the current PQQ literature.
Gomes et al. (2013) established the foundational link between declining NAD+ and disrupted nuclear-mitochondrial communication during aging, providing the mechanistic rationale for NAD+ precursor supplementation. Niu et al. (2023) added data on serum metabolism, fecal microbiota, and telomere length changes with short-term NMN use in pre-aging populations. For readers interested in evidence-based mitochondrial support, bioavailability considerations are critical when comparing these compounds.
CoQ10 (ubiquinone) is another comparator. It is an electron carrier in the mitochondrial respiratory chain and has robust human evidence for heart failure, statin-induced myopathy, and migraine prevention. PQQ is sometimes combined with CoQ10 in supplements, but this pairing is driven more by theoretical synergy than by clinical trial data demonstrating additive effects.
What the Evidence Doesn't Show
It is important to be clear about the limitations. No human study has demonstrated that PQQ supplementation increases mitochondrial number, mitochondrial DNA copy number, or oxidative capacity in muscle or brain tissue. The animal and cell data are promising but preliminary.
Additionally, PQQ is not an essential nutrient in humans. It was originally classified as a novel vitamin, but subsequent research showed that humans do not develop deficiency symptoms in its absence. The body appears to synthesize trace amounts, and it is present in small quantities in foods like kiwi, papaya, spinach, and human breast milk. This means PQQ supplementation is pharmacological rather than nutritional — it is intended to produce effects beyond correcting a deficiency.
Long-term safety data in humans are also sparse. Short-term trials (up to 12 weeks) have not reported serious adverse events at doses of 20–60 mg/day, but there are no published studies examining multi-year use. For anyone considering PQQ as part of a long-term regimen, this uncertainty should factor into the decision.
Who Benefits Most
Given the current evidence, PQQ supplementation is most rational for specific populations and use cases — not as a universal mitochondrial enhancer.
Older adults experiencing fatigue or cognitive decline: Small RCTs suggest PQQ may improve subjective energy and sleep quality in middle-aged and older adults. These effects are modest and may be partially attributable to placebo or general antioxidant activity, but they are not inconsistent with the mechanistic data.
Individuals stacking mitochondrial support: Some consumers take PQQ alongside CoQ10, NMN, or other mitochondrial-targeted supplements based on the rationale of complementary mechanisms. For those already using Bio:sudo NMN 1000mg to support NAD+ levels and cellular energy metabolism, adding PQQ could theoretically provide parallel support through PGC-1α signaling — though this specific combination has not been tested in clinical trials.
People with specific mitochondrial concerns: Individuals with diagnosed mitochondrial disorders should not self-treat with PQQ. However, those with subclinical concerns about age-related mitochondrial decline — particularly if they have ruled out other causes of fatigue — may consider a time-limited trial with objective tracking of symptoms.
Healthy young adults with normal mitochondrial function are unlikely to derive measurable benefit from PQQ supplementation. The Supplement Beginner Guide covers how to evaluate whether any supplement is appropriate for your individual situation.
Practical Takeaways
- PQQ has compelling mechanistic data for mitochondrial biogenesis in cells and animals, but no human trial has directly measured this outcome.
- Small human studies suggest PQQ may improve subjective fatigue, sleep quality, and stress markers at doses of 20 mg/day — but evidence quality is low to moderate.
- PQQ is not an essential nutrient; supplementation is pharmacological, not nutritional.
- For those seeking evidence-based mitochondrial and metabolic support, NMN has stronger human data for functional outcomes like insulin sensitivity and aerobic capacity.
- Long-term safety data beyond 12 weeks are not published; use caution with extended supplementation.
- Always verify supplement quality: look for third-party testing and clear labeling of PQQ content per serving. The How to Read Supplement Labels guide explains what to check.
Bottom Line
PQQ is a biologically interesting compound with solid preclinical evidence for activating mitochondrial biogenesis pathways, but the leap from cultured cells to human outcomes has not been made. For now, it is a reasonable experimental supplement for older adults seeking fatigue or sleep support, not a proven mitochondrial builder. If your goal is evidence-based metabolic and cellular energy support, compounds with stronger human trial data — like NMN, which has demonstrated effects on insulin sensitivity, NAD+ levels, and aerobic capacity — offer a more grounded starting point.
References
- Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
- Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
- Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
- Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
- Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
- Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]